<DOC>
	<DOCNO>NCT01231074</DOCNO>
	<brief_summary>Recent limit short term study show Metformin slow weight gain obese child child psychotropic-induced weight gain , two distinct pediatric population risk obesity relate co-morbid condition . The purpose study conduct long term prospective pilot cohort study investigate use Metformin prevent decrease weight gain two cohort child : 1 ) child psychotropic induced weight gain Metformin 2 ) child BMI 95th percentile Metformin . Both study population enrol lifestyle weight management program</brief_summary>
	<brief_title>Reducing Antipsychotic-Induced Weight Gain Children With Metformin</brief_title>
	<detailed_description>Approximately 21 percent child , 12-17 year old diagnose DSM IV disorder , 11 percent exhibit severe impairment 5 percent severe emotional difficulty . By 18 year , 1-5 percent child diagnose bipolar disorder 20 percent child depression . As great number child adolescent diagnose disorder last 10 year , use psychotropic drug pediatric population increase . Many drug prescribe new antipsychotic drug olanzapine , risperidone , quetiapine , refer atypical antipsychotic . Compared old drug , haldol thorazine , atypical antipsychotic boast improved safety profile , few side effect tardive dyskinesia , extrapyramidal symptom hyperprolactinemia . This advantage lead provider prescribe antipsychotic frequently psychotic condition , also behavioral problem , eg. , oppositional defiant disorder , mood disorder , autism spectrum disorder . In many way , medicine life save . They protect child fate psychosis , unchecked rage agitation , allow chance grow normally . Our study provide preliminary evidence feasibility use metformin adjunct weight management two vulnerable pediatric population . We apply external funding large scale randomize clinical trial test efficacy metformin study population appropriate comparison group . In addition , result exploratory analysis patient characteristic eg. , insulin level , eat behavior ) may affect response treatment provide basis generate hypothesis mechanism action . Primary objective : Describe compare pattern change weight trajectory ( PIW ) ( OME ) group . Secondary Objective : To conduct preliminary investigation factor ( Baseline BMI , adherence , presence gastrointestinal side effect , HOMA-IR , eat pattern ) influence response metformin .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Psychotropic Drugs</mesh_term>
	<criteria>1 . Children age 1017 2 . Currently prescribe one follow psychotropic medication : Haloperidol , perphenazine , clozapine , olanzapine , risperidone , quetiapine , ziprasidone , aripiprazole , thioridazine , chlorprothixene , loxapine , mesoridazine , thiothixene trifluoperazine . 3 . Documented weight gain prescribe medication 4 . Either &gt; 5 % weight increase start medication 3 month , cross 95th percentile BMI , cross 8595th percentile plus one obesity relate complication . 5 . Children age 1017 year old BMI &gt; 95th percentile fast insulin level &gt; 21.7U/L currently psychotropic medication 1 . History liver disease 2 . History kidney disease 3 . Abnormal creatinine 4 . Abnormal liver function blood level</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>obesity</keyword>
	<keyword>weight gain</keyword>
	<keyword>metformin</keyword>
	<keyword>psychotropic drug</keyword>
</DOC>